{"id":7266,"date":"2024-10-31T14:17:00","date_gmt":"2024-10-31T13:17:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-presenterat-nex-22-pa-podd-i-boston\/"},"modified":"2024-10-31T14:17:00","modified_gmt":"2024-10-31T13:17:00","slug":"nanexa-har-presenterat-nex-22-pa-podd-i-boston","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-har-presenterat-nex-22-pa-podd-i-boston\/","title":{"rendered":"Nanexa har presenterat NEX-22 p\u00e5 PODD i Boston"},"content":{"rendered":"
\n

Nanexas presentation av NEX-22 emottogs med stort intresse p\u00e5 den globala konferensen PODD i Boston.<\/strong><\/p>\n<\/div>\n

\n

Nanexa har tidigare i veckan deltagit p\u00e5 konferensen PODD (Partnership Opportunities in Drug Delivery) i Boston. PODD \u00e4r en av de mest betydelsefulla \u00e5rliga konferenserna f\u00f6r Nanexa d\u00e5 den \u00e4r specialiserad p\u00e5 drug delivery och samlar stora globala l\u00e4kemedelsbolag som deltagare.<\/p>\n

Nanexas VD David Westberg presenterade PharmaShell\u00ae teknologin p\u00e5 konferensen, framf\u00f6r allt med fokus NEX-22 projektet. NEX-22 \u00e4r Nanexas dep\u00e5formulering av GLP-1 analogen liraglutid med PharmaShell, f\u00f6r behandling av typ 2 diabetes med administrering en g\u00e5ng i m\u00e5naden. Liraglutid \u00e4r en substans som utvecklats och marknadsf\u00f6rs av Novo Nordisk f\u00f6r dagliga injektioner och d\u00e4r patentet g\u00e5tt ut i USA tidigare i \u00e5r.<\/p>\n

I presentationsprogrammet p\u00e5 PODD \u00e5terkom ett flertal f\u00f6retag till marknadsutvecklingen av GLP-1 behandling inom typ 2 diabetes och obesitas. Speciellt behovet av en produkt som ges mer s\u00e4llan, som en enm\u00e5nads produkt, uttrycktes b\u00e5de fr\u00e5n Novo Nordisk och Eli Lilly. Framf\u00f6r allt f\u00f6r att f\u00f6renkla f\u00f6r patienterna och \u00f6ka deras efterlevnad till den ordinerade behandlingen, men ocks\u00e5 f\u00f6r att f\u00f6rb\u00e4ttra situationen utifr\u00e5n ett milj\u00f6perspektiv.<\/p>\n

Ut\u00f6ver Nanexas egen v\u00e4lbes\u00f6kta presentation hade Nanexa separata m\u00f6ten med ett flertal stora l\u00e4kemedelsbolag som arbetar inom diabetes- och obesitasomr\u00e5det och andra indikationsomr\u00e5den d\u00e4r det finns behov av en dep\u00e5formulering.<\/p>\n

\u201dDet \u00e4r fantastiskt roligt att representera Nanexa i dessa sammanhang och ha m\u00f6jligheten att som enda bolag presentera ett p\u00e5g\u00e5ende kliniskt projekt med en dep\u00e5formulering av en GLP-1 analog. Helt klart har intresset f\u00f6r NEX-22 \u00f6kat \u00e4n mer och \u00e4ven intresset f\u00f6r PharmaShell som drug delivery teknologi f\u00f6r andra indikationsomr\u00e5den. Det ska bli mycket intressant n\u00e4r vi kan presentera resultat fr\u00e5n v\u00e5r kliniska NEX-22 studie senare i \u00e5r och d\u00e5 ocks\u00e5 kan f\u00f6lja upp med de bolagen som visat s\u00e4rskilt intresse i projektet.\u201d s\u00e4ger VD David Westberg<\/p>\n<\/div>\n

\n

F\u00f6r mer information kontakta:<\/strong><\/p>\n

\n

David Westberg \u2013 VD, Nanexa AB (publ)\u00a0
Telefon: 0709-42 83 03
E-post:\u00a0david.westberg@nanexa.se<\/a>
www.nanexa.com<\/a><\/p>\n

Bolagets Certified Adviser \u00e4r Carnegie Investment Bank AB (publ).<\/p>\n<\/div>\n

\n

Om Nanexa AB (publ)<\/strong><\/p>\n

\n

Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n

Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n

\n

Bifogade filer<\/strong><\/p>\n

\n

Nanexa har presenterat NEX-22 p\u00e5 PODD i Boston<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Nanexas presentation av NEX-22 emottogs med stort intresse p\u00e5 den globala konferensen PODD i Boston.<\/p>\n","protected":false},"template":"","class_list":["post-7266","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nNanexa har presenterat NEX-22 p\u00e5 PODD i Boston - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-har-presenterat-nex-22-pa-podd-i-boston\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa har presenterat NEX-22 p\u00e5 PODD i Boston - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexas presentation av NEX-22 emottogs med stort intresse p\u00e5 den globala konferensen PODD i Boston.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-har-presenterat-nex-22-pa-podd-i-boston\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-har-presenterat-nex-22-pa-podd-i-boston\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-har-presenterat-nex-22-pa-podd-i-boston\\\/\",\"name\":\"Nanexa har presenterat NEX-22 p\u00e5 PODD i Boston - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2024-10-31T13:17:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-har-presenterat-nex-22-pa-podd-i-boston\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-har-presenterat-nex-22-pa-podd-i-boston\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-har-presenterat-nex-22-pa-podd-i-boston\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa har presenterat NEX-22 p\u00e5 PODD i Boston\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa har presenterat NEX-22 p\u00e5 PODD i Boston - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-presenterat-nex-22-pa-podd-i-boston\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa har presenterat NEX-22 p\u00e5 PODD i Boston - Nanexa AB","og_description":"Nanexas presentation av NEX-22 emottogs med stort intresse p\u00e5 den globala konferensen PODD i Boston.","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-presenterat-nex-22-pa-podd-i-boston\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-presenterat-nex-22-pa-podd-i-boston\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-presenterat-nex-22-pa-podd-i-boston\/","name":"Nanexa har presenterat NEX-22 p\u00e5 PODD i Boston - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2024-10-31T13:17:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-presenterat-nex-22-pa-podd-i-boston\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-har-presenterat-nex-22-pa-podd-i-boston\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-presenterat-nex-22-pa-podd-i-boston\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa har presenterat NEX-22 p\u00e5 PODD i Boston"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/7266","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=7266"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}